Scarica l'app Stockscreener
0.5512
7.52%
-0.0448
Dopo l'orario di chiusura:
.56
0.0088
+1.60%
Precedente Chiudi:
$0.596
Aprire:
$0.5636
Volume 24 ore:
481.48K
Relative Volume:
1.07
Capitalizzazione di mercato:
$11.76M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.0824
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
-12.09%
1M Prestazione:
-13.87%
6M Prestazione:
-54.45%
1 anno Prestazione:
-66.59%
Intervallo 1D:
$0.5401
$0.5769
Intervallo di 1 settimana:
$0.5333
$0.6269
Portata 52W:
$0.5333
$2.24
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Confronta LGVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5512 | 12.71M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
What technical signals suggest for Longeveron Inc. stockEarnings Summary Report & Fast Moving Stock Trade Plans - Улправда
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction - Investing.com Canada
Longeveron granted U.S. patent for method of treating female sexual dysfunction - marketscreener.com
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction By Investing.com - Investing.com South Africa
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy - The Manila Times
Stem cell approach to women’s sexual dysfunction just won a U.S. patent - Stock Titan
Block Trades: What risks investors should watch in Longeveron Inc stockRate Cut & Free High Return Stock Watch Alerts - moha.gov.vn
Longeveron Earnings Notes - Trefis
Longeveron granted Canadian patent covering laromestrocel administration - MSN
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Prepare Yourself for Liftoff: Longeveron Inc (LGVN) - Setenews
Update Recap: Can MCK stock sustain institutional flowsWatch List & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Longeveron executives to speak at CVCT Forum on cell therapy trials - Investing.com Nigeria
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum - The Manila Times
Longeveron (NASDAQ: LGVN) CSO, CMO to Join CVCT Forum Panels on Cell Therapy Trials - Stock Titan
Can Longeveron Inc. stock continue upward trendWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Longeveron (LGVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Longeveron receives Canadian patent for stem cell therapy By Investing.com - Investing.com Nigeria
Perhaps timely catching Longeveron Inc (LGVN) would be a good idea - Setenews
Longeveron receives Canadian patent for stem cell therapy - Investing.com
Longeveron granted Canadian patent for method of using stem cells to treat non-ischemic dilated cardiomyopathy - MarketScreener
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - The Manila Times
Longeveron (NASDAQ: LGVN) gets Canada patent on LOMECEL-B for frailty and NIDCM - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial By Investing.com - Investing.com South Africa
Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025 - TipRanks
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) sees MRI inflammation drop in 13 of 14 brain regions at week 39 - Stock Titan
Longeveron’s stem cell therapy shows reduced neuroinflammation in AD trial - Investing.com
Longeveron (NASDAQ:LGVN) Shares Up 3% – Should You Buy? - Defense World
Longeveron announces board member resignation - MSN
Is Longeveron Inc. stock a buy in volatile marketsJuly 2025 Price Swings & Safe Swing Trade Setups - moha.gov.vn
Longeveron Inc. (LGVN) Jumps 6% in Pre-market: What’s Driving the Move? - Stocks Telegraph
Longeveron granted U.S. patent for administration of MSCs - MSN
Will Longeveron Inc. stock attract more institutional investorsJuly 2025 Selloffs & Entry Point Confirmation Signals - BỘ NỘI VỤ
Longeveron Inc. (LGVN) 5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take off with Longeveron Inc (LGVN): Get ready for trading - Setenews
What data driven models say about Longeveron Inc.’s futureJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Longeveron Inc. (LGVN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Longeveron to present Alzheimer's treatment data at CTAD 2025 By Investing.com - Investing.com Nigeria
Longeveron to present Alzheimer’s treatment data at CTAD 2025 By Investing.com - Investing.com Australia
Will Longeveron Inc. stock remain a Wall Street favorite2025 Dividend Review & Community Shared Stock Ideas - newser.com
Longeveron to present Alzheimer’s treatment data at CTAD 2025 - Investing.com
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) - The Manila Times
Longeveron (NASDAQ: LGVN) Presenting Laromestrocel CLEAR MIND Data at CTAD 2025 - Stock Titan
Why analysts upgrade Longeveron Inc. stock2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Visualizing Longeveron Inc. stock with heatmapsJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
What drives Longeveron Inc stock priceHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
What dividend safety score for Longeveron Inc. stockWeekly Risk Report & Entry Point Confirmation Signals - newser.com
How Longeveron Inc. stock compares to growth peersJuly 2025 Big Picture & Expert Verified Movement Alerts - Fundação Cultural do Pará
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Longeveron Inc Azioni (LGVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.31%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):